3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
11
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
21
Stomach Neoplasms
19
Ovarian Neoplasms
18
Colorectal Neoplasms
17
Melanoma
15
Carcinoma, Hepatocellular
15
Carcinoma, Non-Small-Cell Lung
12
Breast Neoplasms
11
Uterine Cervical Neoplasms
9
Neoplasm Metastasis
9
Esophageal Neoplasms
9
Liver Neoplasms
7
Head and Neck Neoplasms
7
Anus Neoplasms
7
Colonic Neoplasms
6
Carcinoma, Renal Cell
6
Vaginal Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Penile Neoplasms
5
Neoplasms
5
Mesothelioma
5
Lung Neoplasms
5
Triple Negative Breast Neoplasms
4
Oropharyngeal Neoplasms
4
Neuroblastoma
4
Gastrointestinal Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Merkel Cell
4
Vulvar Neoplasms
3
Urinary Bladder Neoplasms
3
Interventions
Bevacizumab
6
Nivolumab
5
pembrolizumab
4
Gemcitabine
4
Cisplatin
3
regorafenib
2
fludarabine
2
Sorafenib
2
Paclitaxel
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Drug Therapy
2
Cyclophosphamide
2
Azacitidine
2
vocimagene amiretrorepvec
1
ulixertinib
1
temsirolimus
1
spartalizumab
1
sonidegib
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
pazopanib
1
olutasidenib
1
olaparib
1
motexafin gadolinium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Glioblastoma
×
fludarabine
×
Gastrointestinal
×
Clear all
NCT07523529
2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2
Recruiting
72 enrolled
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled